Navigation Links
Scientists show how gene variant linked to ADHD could operate
Date:8/16/2011

A study using mice provides insight into how a specific receptor subtype in the brain could play a role in increasing a person's risk for attention-deficit hyperactivity disorder (ADHD). The research, conducted by the Intramural Research Program (IRP) at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, could also help explain how stimulants work to treat symptoms of ADHD.

Dysfunction of the dopamine D4 receptor subtype is linked to ADHD as well as other disorders characterized by decreased impulse control, including drug abuse. One subtype variant, D4.7, has been of particular interest because of its increased prevalence in those diagnosed with ADHD. However, the function of this particular variant in ADHD has been poorly understood.

In the study, published in today's Molecular Psychiatry, researchers inserted three variants of the dopamine D4 receptor into cells and into mice so that they could investigate differences in biological activities. The researchers found that the D4.7 variant, unlike its D4.2 and D4.4 counterparts, was not able to interact with the short version of the dopamine type 2 (D2S) receptor to reduce glutamate release in a brain region associated with impulsivity and symptoms of ADHD in humans.

"Although previous studies have shown that dysfunctional dopamine D4 receptors are implicated in ADHD, this is the first study to show how this genetic difference might translate into functional deficits seen with this disorder," said NIDA Director Dr. Nora D. Volkow. "Further research is needed to explore how this deficient interaction between receptors might be remedied, which could then lead to new medications for the treatment of ADHD."

Children with ADHD have trouble paying attention and controlling impulsive behaviors, and may be overly active, often resulting in poor school performance and social difficulties. They are also at increased risk for substance use disorders, particularly if their symptoms go untreated.

ADHD is the most commonly diagnosed neurobehavioral disorder of childhood, and the number of children diagnosed continues to rise. According to the Center for Disease Control's National Survey of Children's Health, the number of children aged 4-17 years that were identified by their parent as ever being diagnosed with ADHD increased by 21.8 percent from 2003-2007. By 2007, nearly one in 10 children aged 4-17 years were, at some point, diagnosed with ADHD. Among children with current ADHD diagnoses, 66.3 percent were taking medication for the disorder.

The most commonly used treatment for ADHD involves administering psychostimulant medications. Although these medications alleviate some of the symptoms of ADHD, it is unclear how these compounds act within the brain to do so.

"Our results suggest that psychostimulants might reduce glutamate release by amplifying this D4/D2S interaction," said Dr. Sergi Ferre, primary author for the study. "These results might also explain why these medications are less efficient in patients with the D4.7 variant."


'/>"/>

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Scientists explore the intersection of health, society and microbial ecology
2. Scientists explain unique activity of TB drug pyrazinamide
3. BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
4. Scientists Take Navel-Gazing to New Level
5. Johns Hopkins scientists map genes for common form of brain cancer
6. Scientists May Have Found Missing Link to Common Brain Cancer
7. Have we met before? Scientists show why the brain has the answer
8. Scientists Warn of New Multidrug-Resistant Salmonella
9. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
10. Scientists show swamp gas protects blood vessels from complications of diabetes
11. Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each ... goals for each and every seminar, session and class she offers. ... different brainwave tools which help energize creativity, focus mental functions, enhance athletic focus ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... On Thursday, February 16, 2017, ... at the closing bell, while the Dow Jones Industrial ... Moreover, five out of nine sectors ended Thursday,s trading ... sentiment, Stock-Callers.com assessed the following Medical Appliances & Equipment ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ...
(Date:2/16/2017)... 16, 2017 DaVita Inc. (NYSE: DVA ... December 31, 2016. Net income attributable to ... 2016 was $158 million, or $0.80 per share and $880 ... net income attributable to DaVita Inc. for the quarter and ... below, was $192 million, or $0.98 per share, and $789 ...
(Date:2/16/2017)...  Express Scripts (NASDAQ: ESRX ) was recognized today ... within the Health Care: Pharmacy and Other Services category. ... Most Admired Companies," said Tim Wentworth , CEO and President, ... of our 26,000 employees to make medicine more affordable and accessible ... ...
Breaking Medicine Technology: